{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:10:41Z","timestamp":1790745041542,"version":"4.1.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and Aims<\/jats:title>\n            <jats:p>Free treatments for HCV infection with direct\u2010acting antivirals became widespread in Spain in April 2015. We aimed to test whether, after this intervention, there was a more favorable change in population mortality from HCV\u2010related than from non\u2010HCV\u2010related causes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Approach and Results<\/jats:title>\n            <jats:p>Postintervention changes in mortality were assessed using uncontrolled before\u2013after and single\u2010group interrupted time series designs. All residents in Spain during 2001\u20132018 were included. Various underlying death causes were analyzed: HCV infection; other HCV\u2010related outcomes (HCC, liver cirrhosis, and HIV disease); and non\u2010C hepatitis, other liver diseases, and nonhepatic causes as control outcomes. Changes in mortality after the intervention were first assessed by rate ratios (RRs) between the postintervention and preintervention age\u2010standardized mortality rates. Subsequently, using quasi\u2010Poisson segmented regression models, we estimated the annual percent change (APC) in mortality rate in the postintervention and preintervention periods. All mortality rates were lower during the postintervention period, although RRs were much lower for HCV (0.53; 95% CI, 0.51\u20130.56) and HIV disease than other causes. After the intervention, there was a great acceleration of the downward mortality trend from HCV, whose APC went from \u22123.2% (95% CI, \u22123.6% to \u22122.8%) to \u221218.4% (95% CI, \u221220.6% to \u221216.3%). There were also significant accelerations in the downward trends in mortality from HCC and HIV disease, while they remained unchanged for cirrhosis and slowed or reversed for other causes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These results suggest that the favorable changes in HCV\u2010related mortality observed for Spain after April 2015 are attributable to scaling up free treatment with direct\u2010acting antivirals and reinforce that HCV eradication is on the horizon.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.32237","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:59:58Z","timestamp":1636765198000},"page":"1247-1256","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Favorable impact in hepatitis C\u2013related mortality following free access to direct\u2010acting antivirals in Spain"],"prefix":"10.1097","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7315-034X","authenticated-orcid":false,"given":"Julieta","family":"Politi","sequence":"first","affiliation":[{"name":"National Epidemiology Center,Instituto de Salud Carlos III,Madrid,Spain"},{"name":"Preventive Medicine and Public Health Training Unit PSMar\u2010UPF\u2010ASPB (Parc de Salut Mar\u2010Pompeu Fabra University, Ag\u00e8ncia de Salut P\u00fablica de Barcelona),Barcelona,Spain"},{"name":"National School of Public Health,Instituto de Salud Carlos III,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan\u2010Miguel","family":"Guerras","sequence":"additional","affiliation":[{"name":"National Epidemiology Center,Instituto de Salud Carlos III,Madrid,Spain"},{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Donat","sequence":"additional","affiliation":[{"name":"National School of Public Health,Instituto de Salud Carlos III,Madrid,Spain"},{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J.","family":"Belza","sequence":"additional","affiliation":[{"name":"National School of Public Health,Instituto de Salud Carlos III,Madrid,Spain"},{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ronda","sequence":"additional","affiliation":[{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica,Madrid,Spain"},{"name":"Preventive Medicine and Public Health Area,Universidad de Alicante,Alicante,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Barrio","sequence":"additional","affiliation":[{"name":"National School of Public Health,Instituto de Salud Carlos III,Madrid,Spain"},{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Regidor","sequence":"additional","affiliation":[{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica,Madrid,Spain"},{"name":"Department of Public Health & Maternal and Child Health,Faculty of Medicine,Universidad Complutense,Madrid,Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"hep32237-bib-0053-20250824","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","article-title":"Hepatitis C","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"hep32237-bib-0054-20250824","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0140-6736(16)30466-4","article-title":"Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"hep32237-bib-0055-20250824","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","year":"2017","journal-title":"Lancet Glob Health"},{"key":"hep32237-bib-0058-20250824","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hep.29408","article-title":"Impact of sustained virologic response with direct\u2010acting antiviral treatment on mortality in patients with advanced liver disease","volume":"69","year":"2019","journal-title":"Hepatology"},{"key":"hep32237-bib-0059-20250824","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct\u2010acting antiviral treatment: a prospective cohort study","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"hep32237-bib-0060-20250824","article-title":"Human immunodeficiency virus\/hepatitis C virus coinfection in Spain: prevalence and patient characteristics","volume":"3","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"hep32237-bib-0063-20250824","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jclinepi.2018.05.026","article-title":"A methodological framework for model selection in interrupted time series studies","volume":"103","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"hep32237-bib-0064-20250824","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"hep32237-bib-0065-20250824","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","year":"2007","journal-title":"Ann Intern Med"},{"key":"hep32237-bib-0066-20250824","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon\u2010alpha is associated with improved outcome in HCV\u2010related cirrhosis: a retrospective study","volume":"45","year":"2007","journal-title":"Hepatology"},{"key":"hep32237-bib-0067-20250824","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C","volume":"52","year":"2010","journal-title":"Hepatology"},{"key":"hep32237-bib-0068-20250824","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","year":"2010","journal-title":"J Hepatol"},{"key":"hep32237-bib-0069-20250824","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all\u2010cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","year":"2012","journal-title":"JAMA"},{"key":"hep32237-bib-0070-20250824","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/M14-1152","article-title":"Cost\u2010effectiveness of novel regimens for the treatment of hepatitis C virus","volume":"162","year":"2015","journal-title":"Ann Intern Med"},{"key":"hep32237-bib-0071-20250824","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/M14-1313","article-title":"The cost\u2010effectiveness of sofosbuvir\u2010based regimens for treatment of hepatitis C virus genotype 2 or 3 infection","volume":"162","year":"2015","journal-title":"Ann Intern Med"},{"key":"hep32237-bib-0072-20250824","article-title":"Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: the quality\u2010adjusted cost of care","volume":"95","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"hep32237-bib-0073-20250824","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/cid\/cix364","article-title":"Effect of paritaprevir\/ritonavir\/ombitasvir\/dasabuvir and ledipasvir\/sofosbuvir regimens on survival compared with untreated hepatitis C virus\u2010infected persons: results from ERCHIVES","volume":"65","year":"2017","journal-title":"Clin Infect Dis"},{"key":"hep32237-bib-0074-20250824","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2020.02.022","article-title":"Treatment of HCV reduces viral hepatitis\u2010associated liver\u2010related mortality in patients: an ERCHIVES study","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep32237-bib-0075-20250824","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1053\/j.gastro.2018.07.008","article-title":"Changing trends in etiology\u2010based annual mortality from chronic liver disease, from 2007 through 2016","volume":"155","year":"2018","journal-title":"Gastroenterology"},{"key":"hep32237-bib-0076-20250824","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1360-0443.2008.02451.x","article-title":"Problematic heroin use incidence trends in Spain","volume":"104","year":"2009","journal-title":"Addiction"},{"key":"hep32237-bib-0077-20250824","doi-asserted-by":"crossref","first-page":"102614","DOI":"10.1016\/j.drugpo.2019.102614","article-title":"Integration of harm reduction and treatment into care centres for substance use: the Barcelona model","volume":"76","year":"2020","journal-title":"Int J Drug Policy"},{"key":"hep32237-bib-0078-20250824","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.socscimed.2007.05.004","article-title":"More free syringes, fewer drug injectors in the case of Spain","volume":"65","year":"2007","journal-title":"Soc Sci Med"},{"key":"hep32237-bib-0079-20250824","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1360-0443.2011.03759.x","article-title":"Harm reduction interventions for drug injectors or heroin users in Spain: expanding coverage as the storm abates","volume":"107","year":"2012","journal-title":"Addiction"},{"key":"hep32237-bib-0080-20250824","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cgh.2009.11.018","article-title":"A sustained viral response is associated with reduced liver\u2010related morbidity and mortality in patients with hepatitis C virus","volume":"8","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep32237-bib-0081-20250824","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV\u2010related HCC undergoing interferon\u2010free therapy","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep32237-bib-0082-20250824","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1053\/j.gastro.2019.01.027","article-title":"Direct\u2010acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study","volume":"156","year":"2019","journal-title":"Gastroenterology"},{"key":"hep32237-bib-0083-20250824","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","article-title":"Lack of evidence of an effect of direct\u2010acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep32237-bib-0084-20250824","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct\u2010acting antiviral HCV therapy: a systematic review, meta\u2010analyses, and meta\u2010regression","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep32237-bib-0085-20250824","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jhep.2019.04.014","article-title":"Declining hepatitis C virus\u2013related liver disease burden in the direct\u2010acting antiviral therapy era in New South Wales, Australia","volume":"71","year":"2019","journal-title":"J Hepatol"},{"key":"hep32237-bib-0087-20250824","first-page":"1400","article-title":"Changes in alcohol consumption in Spain between 1990 and 2019","year":"2020","journal-title":"Adicciones"},{"key":"hep32237-bib-0088-20250824","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3851\/IMP3117","article-title":"Real\u2010world effectiveness and predictors of sustained virological response with all\u2010oral therapy in 21,242 hepatitis C genotype\u20131 patients","volume":"22","year":"2017","journal-title":"Antivir Ther"},{"key":"hep32237-bib-0089-20250824","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep32237-bib-0090-20250824","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co\u2010infection in people living with HIV: a global systematic review and meta\u2010analysis","volume":"16","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"hep32237-bib-0091-20250824","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/QAD.0000000000000377","article-title":"Mortality in HIV\u2013hepatitis C co\u2010infected patients in Canada compared to the general Canadian population (2003\u20132013)","volume":"28","year":"2014","journal-title":"Aids"},{"key":"hep32237-bib-0092-20250824","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/QAD.0000000000000674","article-title":"Liver\u2010related death among HIV\/hepatitis C virus\u2010co\u2010infected individuals: implications for the era of directly acting antivirals","volume":"29","year":"2015","journal-title":"AIDS"},{"key":"hep32237-bib-0093-20250824","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/cid\/ciz833","article-title":"Eliminating structural barriers: the impact of unrestricted access on hepatitis C treatment uptake among people living with human immunodeficiency virus","volume":"71","year":"2020","journal-title":"Clin Infect Dis"},{"key":"hep32237-bib-0094-20250824","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/QAD.0000000000002156","article-title":"Trends in cause\u2010specific mortality in HIV\u2010hepatitis C coinfection following hepatitis C treatment scale\u2010up","volume":"33","year":"2019","journal-title":"AIDS"},{"key":"hep32237-bib-0095-20250824","doi-asserted-by":"crossref","first-page":"8922","DOI":"10.1038\/s41598-020-65841-0","article-title":"Trends and causes of mortality in a population\u2010based cohort of HIV\u2010infected adults in Spain: comparison with the general population","volume":"10","year":"2020","journal-title":"Sci Rep"},{"key":"hep32237-bib-0097-20250824","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/hep.20463","article-title":"Progression of liver fibrosis in women infected with hepatitis C: long\u2010term benefit of estrogen exposure","volume":"40","year":"2004","journal-title":"Hepatology"},{"issue":"Suppl 3","key":"hep32237-bib-0098-20250824","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1093\/infdis\/jiu057","article-title":"Natural history and management of hepatitis C: does sex play a role?","volume":"209","year":"2014","journal-title":"J Infect Dis"},{"key":"hep32237-bib-0099-20250824","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/157016211797635982","article-title":"Gender differences in liver fibrosis and hepatitis C virus\u2013related parameters in patients coinfected with human immunodeficiency virus","volume":"9","year":"2011","journal-title":"Curr HIV Res"},{"key":"hep32237-bib-0100-20250824","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jhep.2016.06.025","article-title":"Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population\u2010based study","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep32237-bib-0102-20250824","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"hep32237-bib-0103-20250824","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12879-018-3125-6","article-title":"Impact of new DAA therapy on real clinical practice: a multicenter region\u2010wide cohort study","volume":"18","year":"2018","journal-title":"BMC Infect Dis"},{"key":"hep32237-bib-0104-20250824","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/jmv.25552","article-title":"Efficacy of direct\u2010acting antivirals: UK real\u2010world data from a well\u2010characterised predominantly cirrhotic HCV cohort","volume":"91","year":"2019","journal-title":"J Med Virol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.32237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.32237","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T23:06:59Z","timestamp":1756076819000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.32237","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]},"assertion":[{"value":"2021-04-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}